 LAWRENCEVILLE, N.J., Nov. 09, 2020 GLOBE NEWSWIRE -- Celsion Corporation NASDAQ: CLSN announced today that the Company will host a conference call to discuss financial results for the third quarter ended September 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system and ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin at 11:00 a.m. ET on Monday, November 16, 2020. 